BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35919033)

  • 1. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
    Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X
    Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-Related Genes CDK1 and COA6 Involved in the Prognosis Prediction of Liver Hepatocellular Carcinoma.
    Han S; Ye T; Mao Y; Hu B; Wang C
    Dis Markers; 2023; 2023():5552798. PubMed ID: 37215201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDCL3 is a prognostic biomarker associated with immune infiltration in hepatocellular carcinoma.
    Jin W; Wang G; Dong M; Wang X
    Eur J Med Res; 2024 Mar; 29(1):177. PubMed ID: 38494503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
    Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
    Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
    Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
    PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Model of Basement Membrane-Associated Gene Signature Predicts Liver Hepatocellular Carcinoma Response to Immune Checkpoint Inhibitors.
    Shen J; Wei Z; Lv L; He J; Du S; Wang F; Wang Y; Ni L; Zhang X; Pan F
    Mediators Inflamm; 2023; 2023():7992140. PubMed ID: 37152370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
    Yan C; Niu Y; Ma L; Tian L; Ma J
    J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis unveils ECM signatures and pathways driving hepatocellular carcinoma progression: A multi-omics approach and prognostic model development.
    Liu Z; Zhao P
    J Cell Mol Med; 2024 Apr; 28(8):e18230. PubMed ID: 38568083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation Mitochondrial Carrier 1 (MTCH1) Is Associated with Cell Proliferation, Invasion, and Migration of Liver Hepatocellular Carcinoma.
    Chen G; Mo S; Yuan D
    Biomed Res Int; 2021; 2021():9911784. PubMed ID: 34195286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential crucial genes associated with the pathogenesis and prognosis of liver hepatocellular carcinoma.
    Shi L; Shang X; Nie K; Lin Z; Zheng M; Wang M; Yuan H; Zhu Z
    J Clin Pathol; 2021 Aug; 74(8):504-512. PubMed ID: 33004423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
    He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
    Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of HILPDA is an adverse prognostic prognostic factor in hepatocellular carcinoma.
    Wang X; Zou A; Zhang J; Gao G; Shan W; Li J; Liu X
    Medicine (Baltimore); 2023 Mar; 102(9):e33145. PubMed ID: 36862910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic prediction and multidimensional dissections of a macrophages M0-related gene signature in liver cancer.
    Xu X; Wang J
    Front Endocrinol (Lausanne); 2023; 14():1153562. PubMed ID: 37033261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of N
    Zhu HX; Lu WJ; Zhu WP; Yu S
    J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferroptosis regulator SLC7A11 is a prognostic marker and correlated with PD-L1 and immune cell infiltration in liver hepatocellular carcinoma.
    Liang Y; Su S; Lun Z; Zhong Z; Yu W; He G; Wang Q; Wang J; Huang S
    Front Mol Biosci; 2022; 9():1012505. PubMed ID: 36267158
    [No Abstract]   [Full Text] [Related]  

  • 16. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
    Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
    Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of RNF31 is associated with tumor immune cell infiltration and leads to poor prognosis in liver hepatocellular carcinoma.
    Xi G; Cheng R; Liang L; Che N; Wang Y; Zhao N; Liang X; Shao B; Zhao X; Zhang D
    Sci Rep; 2023 Apr; 13(1):6957. PubMed ID: 37117215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
    Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
    Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
    Yu Y; Lou Y; Zhu J; Wang X
    Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
    Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
    Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.